Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propane SCHEMBL28183675 | 0.85 | LMNA (0.33) | LMNAKDM4E | |
| Alcohol SCHEMBL20856433 | 0.82 | ALDH1A1 (0.33) | LMNAKDM4EALDH1A1 | |
| Ethyl Chloride SCHEMBL28823879 | 0.80 | LMNA (0.31) | LMNA | |
| Methyl Alcohol SCHEMBL28183931 | 0.79 | BRD4 (0.33) | KDM4E | |
| SCHEMBL338264 | 0.79 | KDM4E (0.34) | KDM4EALDH1A1 | |
| SCHEMBL1123 | 0.79 | — | — | |
| SCHEMBL785147 | 0.79 | — | — | |
| Ethyl Acetate SCHEMBL7351694 | 0.79 | ALDH1A1 (0.56) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| Pentane SCHEMBL28218834 | 0.78 | FAAH (0.39) | LMNAKDM4EKMT2AALDH1A1 | |
| Urethane SCHEMBL4882078 | 0.77 | ALOX15 (0.58) | LMNAKDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389298-B2 | Methods using novel chemiluminescent labels | LUMIGEN, INC. (US) | 2013-03-05 | — | — | US | claimed |
| US-20100190271-A1 | METHODS USING NOVEL CHEMILUMINESCENT LABELS | LUMIGEN, INC. (US) | 2010-07-29 | — | — | US | claimed |
| US-20100173429-A1 | METHODS USING NOVEL CHEMILUMINESCENT LABELS | LUMIGEN, INC. (US) | 2010-07-08 | — | — | US | claimed |
| US-20080113924-A1 | Neuramindase Inhibitor | NATIONAL INSTITUE OF ADVANCE INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-05-15 | — | — | US | claimed |
| US-20070172878-A1 | Methods using novel chemiluminescent labels | LUMIGEN, INC. | 2007-07-26 | — | — | US | claimed |
| US-20060205094-A1 | Methods using novel chemiluminescent labels | LUMIGEN, INC. | 2006-09-14 | — | — | US | claimed |
| US-RE49466-E1 | Solution phase homogeneous assays | BECKMAN COULTER, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-10603338-B2 | Method for poly signal activation of apoptosis of malignant solid tumour cells | OBSHESTVO S ORGANICHENNOI OTVETSTVENNOST'YU “BIOTEHNOLOGIYA” (RU) | 2020-03-31 | — | — | US | disclosed |
| US-20180250331-A1 | Method for Poly Signal Activation of Apoptosis of Malignant Solid Tumour Cells | OBSHESTVO S OGRANICHENNOI OTVETSTVENNOST'YU "BIOTEHNOLOGIYA" (RU) | 2018-09-06 | — | — | US | disclosed |
| EP-3354270-A1 | METHOD FOR POLY SIGNAL ACTIVATION OF APOPTOSIS OF MALIGNANT SOLID TUMOUR CELLS | Obshestvo S Ogranichennoi Otvetstvennost'yu "Biotehnologiya" (RU) | 2018-08-01 | — | — | EP | disclosed |
| US-10036708-B2 | Solution phase homogeneous assays | BECKMAN COULTER, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2021778-B1 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2027453-B1 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2021778-A1 | NONSEPARATION ASSAY METHODS | Beckman Coulter, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080113924-A1 | Neuramindase Inhibitor | NATIONAL INSTITUE OF ADVANCE INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-05-15 | — | — | US | disclosed |
| WO-2007134098-A1 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007133988-A1 | NONSEPARATION ASSAY METHODS | BECKMAN COULTER, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070264664-A1 | Nonseparation assay methods | NEXGEN DIAGNOSTICS LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070264665-A1 | Nonseparation assay methods | BECKMAN COULTER, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20060205094-A1 | Methods using novel chemiluminescent labels | LUMIGEN, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113924-A1 | Neuramindase Inhibitor | NMBR, NEU1, NMUR1 | LMNA 3776/4885KDM4E 4523/4885MEN1 2118/4885 |
| US-20070172878-A1 | Methods using novel chemiluminescent labels | HLCS, LANCL1, ACR | LMNA 904/4885KDM4E 2463/4885MEN1 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.